SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has had an abstract accepted for presentation at the International Scientific Conference on Probiotics and Prebiotics in Budapest, Hungary from 20 – 22 June 2017 (IPC2017).
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that it has signed two new exclusive distribution agreements for its EarlyCDT®-Lung test with Best Medical Opinion and Dow Biomedica/Biodiscovery in Israel and Korea respectively.
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced positive topline results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).
SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM 5 March 2017 under the ticker code SBTX and the ISIN number: GB00BF33H870.
Share Talk spoke to Declan Service, CEO of Integumen Plc about today’s IPO to the FTSE AIM market after a fundraise of £2.25M.
Share Talk presents a video of João Andrade’s investor presentation from our Innovative Investor’s Evening at the National Museum in Cardiff, 18 February 2017, sponsored by Financial Orbit Ltd and supported by SC Capital Ltd, St Brides Partners and Companies House.
This morning OptiBiotix Health Plc (AIM:OPTI) released significant news that they have signed a major manufacturing, supply and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.